Ablynx wins €2.1m grant from Flemish Agency for Innovation by Science and Technology

Published: 13-Aug-2014
Research & Development Finance

To support development of nanobodies for ocular applications


Belgian biopharmaceutical company Ablynx has been awarded a €2.1m grant by the Flemish Agency for Innovation by Science and Technology (IWT) to help advance a novel approach to the treatment of diseases of the eye using some of the unique characteristics of nanobodies.

The grant is available over a period of three years and will allow the development and subsequent testing of nanobody leads in relevant pre-clinical disease models.

'Ophthalmology is an increasingly important area for many pharmaceutical companies as they seek to meet the demands of an ageing population,' said Tony De Fougerolles, CSO of Ablynx.

  • Companies:
  • Ablynx nv
See more

You may also like

Media

Sanofi completes acquisition of Ablynx

Read more
Sanofi has now acquired all outstanding shares, warrants and convertible bonds of Ablynx following the expiration of the Squeeze-out procedure

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  4. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Media

Sanofi completes acquisition of Ablynx

Sanofi has now acquired all outstanding shares, warrants and convertible bonds of Ablynx following the expiration of the Squeeze-out procedure
Research & Development

Sanofi to acquire Ablynx for €3.9 billion

The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on addressing multiple disease targets with single multi-specific molecules
Research & Development

Novel Nanobody to begin clinical development in osteoarthritis

Ablynx to receive €15m milestone payment from Merck
Ingredients

Ablynx acheives first milestone as part of collaboration with Novo Nordisk

Multi-specific nanobody candidate reaches discovery milestone
Finance

Ablynx raises €74.2m in share placement

Belgian firm will use proceeds to fund clinical development and commercialisation of its most advanced assets
Regulatory

Ablynx to receive an €8m milestone payment as Boehringer Ingelheim starts a Phase I study with an anti-CX3CR1 nanobody

The anti-CX3CR1 nanobody was discovered and developed as part of a longstanding strategic alliance between both parties
Research & Development

Ablynx to work with Novo Nordisk on nanobody drug discovery

Will receive a €5m upfront payment, research funding and potential future milestones and royalties on net sales
Subscribe now